Jing Ping Yeo: Establishment of the Asia Pacific Oncology Drug Development Consortium
Jing Ping Yeo, Head of transformation, Operational Enablers, Commercial Excellence, Accelerate Growth at George Clinical, shared a post on LinkedIn:
“The Asia Pacific region exhibits significant disparities in disease epidemiology, healthcare standards, and access to healthcare. These differences are also reflected in the capabilities and infrastructure for translational and clinical research, as well as in varying regulatory processes and reimbursement systems.
It is encouraging to see the establishment of the Asia Pacific Oncology Drug Development Consortium (APODDC), which aims to advance oncology drug development through collaborative projects and information sharing among dedicated trial sites.
On July 19, approximately 200 clinicians and industry partners attended a 1-day symposium to discuss the latest trends in oncology clinical trials, the use of cell and gene therapies, and regulatory expectations for conducting trials and securing product registrations.
Thank you to APODDC led by Herbert Loong, MBBS FRCP FASCO, Daniel SW Tan and Toshio Shimizu for providing industry members with the opportunity to participate and learn. It is crucial for all research stakeholders within the ecosystem to collaborate, communicate, and connect!”
Source: Jing Ping Yeo/LinkedIn
